

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/515,934	
				FILING DATE		May 19, 2006	
				APPLICANT		Mercep et al.	
				GROUP		1614	
				EXAMINER		A.M. Lewis	
				ATTORNEY DOCKET NO.		PLP529USw	
U.S. PATENT DOCUMENTS 11/08/2009							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	3,773,940	11/20/1973	Schindler et al.			
	2	3,781,294	Dec. 25, 1973	Lombardino			
	3	3,859,439	01/07/1975	Blattner and Schindler			
	4	4,112,110	09/15/1978	Blattner			
	5	4,271,179	06/02/1981	van der Burg			
	6	4,267,190	05/12/1981	Cherkofsky et al.			
	7	4,267,184	05/12/1981	Cherkofsky et al.			
	8	7,312,203	12/25/2007	Mercep et al.			
	9	7,435,834	October 2008	Mercep et al.			
	10	US 2005/0148578	07/05/2005	Mercep et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	11	EP 0125484	11/21/1984	Ciba Geigy AG			
	12	EP 0357126	03/07/1990	Akzo N.V.			
	13	HR 20000310	Feb. 28, 2002	CROATIA			X
	14	WO 91/18885	Dec. 12, 1991	WIPO			
	15	WO 98/54186	12/03/1998	Akzo Nobel N.V.			
	16	WO 01/87890	Nov. 22, 2001	WIPO			
	17	WO 03/097648	11/27/2003	Pliva d.d.			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	18	Badger et al. "Pharmacological profile of SB-203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function." J. Pharmac. Env. Therap., 1996, 279(3):1453-1461.					
	19	Bennett et al. "Reaction of 5-acetyl-10, didehydro-5H-dibenz[b,f] azepine with pyrrole, N-methylpyrrole, imada and n-methylimidazole: cycloaddition versus Michael addition." J. Heterocycl. Chem., 1994, 31:293-296.					
	20	Bresnihan. "Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in rheumatoid arthritis (RA); results of randomized double-blind, placebo-controlled multicenter trial." Arthrit. Rheum., 1996, 39:73.					
	21	Carswell et al. "An endotoxin-induced serum factor that causes necrosis of tumors." Proc. Natl. Acad. Sci. U.S.A., 1975, 72:3666-3670.					
	22	Collier et al. "The abdominal constriction response and its suppression by analgesic drugs in the mouse." Br. J. Pharmac. Chemother., 1968, 32:295-310					
	23	Dinarello. "An update on human interleukin-1: From molecular biology to clinical relevance." J. Clinical Immunology, 1985, 5:287.					
	24	Dinarello. "Interleukin-1." Rev. Infect. Disease, 1984, 6(1):51-95.					
	25	Elliott et al. "Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis." The Lancet, 1994, 344:1105-1110.					
	26	Fukawa et al. "A method for evaluating analgesic agents in rats." J. Pharmacol. Meth., 1980, 4:251-259.					
	27	Funke et al. "Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine Maleate. Arzeim-Forsch., 1190, 40:536-539.					
	28	Georgopoulos et al. "Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice." J. Inflamm., 1996, 46:86-97.					
	29	Keffer, et al. "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis." EMBO J., 1991, 10:4025-4031.					

/Amy Lewis/

11/08/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.L./

30	Mattioli and Ghia. "Omega-dialkylaminoalkyl ethers of phenyl-(5-substituted 1-phenyl-1H-pyrazol-4-yl)methanols with analgesic and anti-inflammatory activity." J. Heterocyclic Chem., 1997, 34:963-968.
31	Mori et al. "Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice." J. Immunol., 1996, 157:3178-3182.
32	Novacek et al. "Reaction of 8-chloro-10-phenylhydrazono-10, 11-dihydro-dibenzo[b,f]thepine with aromatic aldehydes." Collection Czechoslov. Chem. Commun., 1976, Vol. 41, 785-787.
33	Pfeffer et al. "Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection." Cell, 1993, 73:457-467.
34	Schulz et al. "Synthese von 1,3a,3,12b-tetrahydro-dibenzo[b,f]-pyrazolo[3,4-d]azepin-Derivaten." Z. Chem. 1988, 28:181-182.
35	Schweizer et al. "Combined automated writhing/motility test for testing analgesics." Agents and Actions, 1988, 23:29-31.
36	Van Assche and Rutgeerts. "Anti-TNF agents in Chrohn's disease." Exp. Opin. Invest. Drugs, 2000, 9:103-111.
37	Wermuth et al. "Molecular Variations Based on Isosteric Replacements." Practice of Medicinal Chemistry, 1996, pages 203-237.
Continue on page _____	
EXAMINER	DATE CONSIDERED
/Amy Lewis/	11/08/2009
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	